Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says
Executive Summary
Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said
You may also be interested in...
Who Needs The BBB? Aduhelm Shows Medicare Price ‘Negotiation’ Is Already Here
Biogen is making clear that its decision to cut the price of the Alzheimer’s therapy Aduhelm is in no way tied to the upcoming US Medicare coverage decision for the treatment. But it still shows how Medicare can already ‘negotiate’ prices even without explicit statutory authority.
The Virtues Of Predictability: US Medicare’s Review Of Aduhelm Coverage
Medicare’s decision to initiate a formal review of coverage for the newly approved Alzheimer’s agent is a highly unsettling development in many respects. It is also probably the best possible news for Biogen and Eisai at this point.
Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo
Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4